现代医药卫生2024,Vol.40Issue(18) :3197-3201,3206.DOI:10.3969/j.issn.1009-5519.2024.18.027

宏基因组二代测序早期检测脓毒症病原体的临床应用进展

Advances in clinical application of metagenomic next-generation sequencing for early detection of pathogens in sepsis

王黎 丁艳辉 曹子鋆 薛建江 王晓亮
现代医药卫生2024,Vol.40Issue(18) :3197-3201,3206.DOI:10.3969/j.issn.1009-5519.2024.18.027

宏基因组二代测序早期检测脓毒症病原体的临床应用进展

Advances in clinical application of metagenomic next-generation sequencing for early detection of pathogens in sepsis

王黎 1丁艳辉 2曹子鋆 1薛建江 1王晓亮1
扫码查看

作者信息

  • 1. 重庆医科大学附属大学城医院医学科学研究中心/检验科,重庆 401331
  • 2. 重庆医科大学附属第一医院检验科,重庆 400016
  • 折叠

摘要

脓毒症患者存活率低、死亡率高、预后差,早期识别其病原体尤为关键.宏基因组二代测序(mNGS)能实现无偏倚检测临床样本中的所有微生物,对早期发现脓毒症病原微生物较传统培养技术等更灵敏、准确、高效.随着二代测序技术的不断发展,mNGS在诊断脓毒症方面的临床应用价值将进一步提高,该文就mNGS在脓毒症早期诊断中的优势、临床应用及进展、挑战与展望进行综述.

Abstract

Sepsis patients have low survival rates,high mortality rates,and poor prognosis,making ear-ly identification of pathogens particularly crucial.Metagenomic next-generation sequencing(mNGS)enables unbiased detection of all microorganisms in clinical samples,providing greater sensitivity,accuracy,and effi-ciency in early detection of sepsis pathogenic microorganism compared to traditional culture techniques.With the continuous development of next-generation sequencing technology,the clinical application value of mNGS in sepsis diagnosis will further improve.This article reviews the advantages,clinical applications,progress,challenges,and prospects of mNGS in the early diagnosis of sepsis.

关键词

宏基因组二代测序/脓毒症/病原微生物/早期检测/综述

Key words

Metagenomic next-generation sequencing/Sepsis/Pathogenic microorganisms/Early detection/Review

引用本文复制引用

基金项目

重庆市自然科学基金项目(cstc2019jcyjmsxmX0294)

重庆市教委科学技术研究项目(KJQN202000444)

出版年

2024
现代医药卫生
重庆市卫生信息中心

现代医药卫生

影响因子:0.758
ISSN:1009-5519
段落导航相关论文